Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. | Despite growing competition ...
Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...
Professor Im Joo Rhyu, director of the Korea University Graduate Program for Convergence & Translational Biomedicine and ...
Our skin and mucous membranes are protected by epithelial cells. This barrier tissue performs its function thanks to specialized structures called junctions. They ensure cell cohesion and regulate ...
3d
Zacks Investment Research on MSNRithm (RITM) Ascends But Remains Behind Market: Some Facts to NoteIn the latest trading session, Rithm (RITM) closed at $11.82, marking a +0.94% move from the previous day. This move lagged the S&P 500's daily gain of 1.08%. At the same time, the Dow added 0.92%, ...
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Ybañez, who sustained a Grade 2 right ankle sprain in their season-opening loss to FEU last February 15, said he’s still getting a feel inside the court as he continues to work his way to full ...
Rithm Capital Trading Up 0.9 % NYSE RITM opened at $11.83 on Friday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.09 and a quick ratio of 1.35. The firm’s fifty day ...
The most well-known form of OTT media services is associated with video streaming. Monthly-based or full-scale video subscription services like Netflix paid stores like iTunes, or ad-supported ...
RITM's full-year Zacks Consensus Estimates are calling for earnings of $1.94 per share and revenue of $4.89 billion. These results would represent year-over-year changes of -7.62% and -6.53% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results